Founded in 2015 and backed by global investors, we’ve built a 60-strong team in Oxford and a core portfolio of 50+ companies – with a pipeline of world-changing ventures still to come.
We’re owned by global shareholders and supported by a network of specialist co-investors who invest alongside us from pre-seed to growth.
Her career path may be unconventional, but Dame Carol’s talent and tenacity has paved the way for a revolution in drug discovery.
She left school in 1972 with few qualifications, but that didn’t stop her going on to become one of the world’s most decorated scientists.
Not only is Dame Carol the first woman to hold a full professorship in Chemistry at both Oxford and Cambridge universities, she’s also the founder of OMass Therapeutics, a trailblazing OSE portfolio company in the biotech sector.
The company builds on Dame Carol’s pioneering work in ‘native mass spectrometry’ – a technique for studying proteins in their natural state. The technique has revolutionised structural biology and paved the way for breakthroughs in small drug discovery.
